Escherichia coli on colorectal cancer: A two‐edged sword

• Published in: Microbial biotechnology Vol. 17; no. 10; pp. e70029 - n/a
• Main Authors: Jian, Chu, Yinhang, Wu, Jing, Zhuang, Zhanbo, Qu, Zefeng, Wang, Shuwen, Han
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.10.2024; John Wiley and Sons Inc; Wiley
• Subjects: Antigens; Bacteria; Biofilms; Biomarkers; Cancer therapies; Coliforms; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - microbiology; DNA methylation; E coli; Environmental factors; Escherichia coli; Escherichia coli - genetics; Gastrointestinal Microbiome; Genes; Genetic engineering; Genomes; Humans; Immunotherapy; Metabolism; Metabolites; Metastasis; Microflora; Microorganisms; Nanoparticles; Phylogenetics; Polymorphism; Probiotics; Review; Science; Tumors
• ISSN: 1751-7915; 1751-7915
• DOI: 10.1111/1751-7915.70029

Escherichia coli (E. coli) is a ubiquitous symbiotic bacterium in the gut, and the diversity of E. coli genes determines the diversity of its functions. In this review, the two‐edged sword theory was innovatively proposed. For the question ‘how can we harness the ambivalent nature of E. coli to screen and treat CRC?’, in terms of CRC screening, the variations in the abundance and subtypes of E. coli across different populations present an opportunity to utilise it as a biomarker, while in terms of CRC treatment, the natural beneficial effect of E. coli on CRC may be limited, and engineered E. coli, particularly certain subtypes with probiotic potential, can indeed play a significant role in CRC treatment. It seems that the favourable role of E. coli as a genetic tool lies not in its direct impact on CRC but its potential as a research platform that can be integrated with various technologies such as nanoparticles, imaging methods, and synthetic biology modification. The relationship between gut microflora and CRC remains unclear due to the complex diversity and interaction of gut microflora. Therefore, the application of E. coli should be based on the ‘One Health’ view and take the interactions between E. coli and other microorganisms, host, and environmental factors, as well as its own changes into account. In this paper, the two‐edged sword role of E. coli in CRC is emphasised to realise the great potential of E. coli in CRC screening and treatment. This review discusses Escherichia coli's (E. coli) dual role in colorectal cancer (CRC) via metabolites, immune modulation, and biofilm formation. It explores E. coli as a CRC biomarker and its therapeutic potential, highlighting its use in integrating advanced technologies for research.